Xenomics Signs Licensing Agreement With Sequenom
Xenomics, a developer of non-invasive next-generation molecular diagnostics, has licensed to Sequenom, a genetics and molecular diagnostics company, exclusive rights to Xenomics patents for the development of prenatal research and diagnostic products based on the company’s proprietary transrenal DNA/RNA technology.
The agreement provides for an upfront payment, equity participation and royalties on sales of licensed products, subject to certain minimum amounts. The license does not cover Xenomics current test for fetal gender determination based solely on detection of Y chromosome.
This agreement represents the company’s first license for applications of its proprietary platform technology. In addition to prenatal diagnostics, Xenomics has patent rights covering the fields of infectious diseases, tumor detection and transplantation. Due to simplicity of sample collection and transrenal-DNA stability, the technology is said to be optimally suitable for screening tests.
Samuil Umansky, chief scientific officer and co-founder of Xenomics, said: “We are pleased to have Sequenom as our licensing partner for these applications of our platform technology. This license offers Sequenom the potential for a broader approach to prenatal diagnostics by using fetal nucleic acids found in easily-obtained maternal urine samples.”